Literature DB >> 27388874

Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.

Anni Hovi1, Laura Airas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27388874     DOI： 10.1007/s11481-016-9697-2

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


× No keyword cloud information.
  6 in total

1.  FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Jerzy-Roch Nofer; Martine Bot; Martin Brodde; Paul J Taylor; Paul Salm; Volker Brinkmann; Theo van Berkel; Gerd Assmann; Erik A L Biessen
Journal:  Circulation       Date:  2007-01-22       Impact factor: 29.690

2.  Forty-year trends in cardiovascular risk factors in Finland.

Authors:  Katja Borodulin; Erkki Vartiainen; Markku Peltonen; Pekka Jousilahti; Anne Juolevi; Tiina Laatikainen; Satu Männistö; Veikko Salomaa; Jouko Sundvall; Pekka Puska
Journal:  Eur J Public Health       Date:  2014-11-24       Impact factor: 3.367

3.  Effects of Three Months Fingolimod Therapy on Heart Rate.

Authors:  Sakari Simula; Tomi Laitinen; Tiina M Laitinen; Tuula Tarkiainen; Juha E K Hartikainen; Päivi Hartikainen
Journal:  J Neuroimmune Pharmacol       Date:  2015-06-20       Impact factor: 4.147

4.  Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  K Huang; S Q Li; W J Wang; L S Liu; Y G Jiang; P N Feng; Y Q Wang; S M Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Apr-Jun       Impact factor: 3.219

5.  Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.

Authors:  Roland Klingenberg; Jerzy-Roch Nofer; Mats Rudling; Florian Bea; Erwin Blessing; Michael Preusch; Hermann J Grone; Hugo A Katus; Göran K Hansson; Thomas J Dengler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-30       Impact factor: 8.311

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.